Advertisement

Topics

BridgeBio Pharma Launches CoA Therapeutics To Target Coenzyme-A For Rare Genetic Disorders

06:00 EDT 14 Jun 2018 | Pharmaceutical Processing

CoA Therapeutics' lead compound will be entering the clinic in 2019 with a planned initial focus on pantothenate kinase-associated neurodegeneration, or PKAN.
Contributed Author: 
BridgeBio Pharma
Topics: 

Original Article: BridgeBio Pharma Launches CoA Therapeutics To Target Coenzyme-A For Rare Genetic Disorders

NEXT ARTICLE

More From BioPortfolio on "BridgeBio Pharma Launches CoA Therapeutics To Target Coenzyme-A For Rare Genetic Disorders"

Advertisement
Quick Search
Advertisement
Advertisement